Researchers conducted a review and meta‑analysis of 11 randomized controlled trials (RTCs) to evaluate the effect of oral magnesium supplementation on plasma C-reactive protein (CRP) concentrations. The analysis was stratified to compare subgroups of populations; those with a baseline plasma CRP values of ≤ 3 and those having CRP values > 3. The difference between the subgroups was statistically significant. There was no significant reduction in the first (≤ 3) subgroup. However, there was a significant reduction in CRP for the latter subgroup (> 3). The results of this meta-analysis indicate that magnesium supplementation reduces CRP levels among individuals with inflammation (as indicated by CRP levels > 3 mg/dL). Researchers concluded that their finding suggests that magnesium supplements may have a beneficial role as an adjuvant for the management of low-grade chronic systemic inflammation.\r\n\r\nSimental-Mendia LE, Sahebkar A, Rodriguez-Moran M, Zambrano-Galvan G, Guerroro-Romero F. Effect of magnesium supplementation of plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des. 2017 May 25. doi: 10.2174/1381612823666170525153605. [Epub ahead of print]